MedPath

A Clinical trial to study the effect of Patha (Cissampelos pariera) in patients with painful menstruation.

Not yet recruiting
Conditions
Primary dysmenorrhea. Ayurveda Condition: kashtartava,
Registration Number
CTRI/2021/09/036512
Lead Sponsor
Himani
Brief Summary

this study is randomized open interventional study, to  measure the efficacy of decoction of *patha* given at  a dose of 50 ml twice a daily for three menstrual cycles that will be conducted in a single centre in india. The primary outcome measures will be the pacification or complete resolution of primary dysmenorrhea by decoction of *patha.* The secondary outcome will be no efficacy of decoction of patha in managing the pain of primary dysmenorrhea.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Female
Target Recruitment
30
Inclusion Criteria

Patients or parents of the young patients who agree to give written consent patients having chief complaint of painful menses patient suffering from primary dysmenorrhoea for more than 3 cycles.

Exclusion Criteria
  • Patients or parents of the young patients who do not agree to give written consent.
  • Patient with chronic systemic illness and uterine pathology like fibroid, adenomyosis, endometriosis.
  • Patient with intrauterine contraceptive devices.
  • Patient suffering from hypothyroidism or Hyperthyroidism.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Menstruation is not painful anymore or is reduced to a substantial amount.3 Months
Secondary Outcome Measures
NameTimeMethod
Menstruation is still painful to the same extent as before Intervention.3 Months

Trial Locations

Locations (1)

Government Ayurvedic Hospital, Patiala

🇮🇳

Patiala, PUNJAB, India

Government Ayurvedic Hospital, Patiala
🇮🇳Patiala, PUNJAB, India
Himani
Principal investigator
7413055970
himania007@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.